NSW Minister for Health Ryan Park with PSA NSW Branch President Luke Kelly FPS[/caption]
[post_title] => Pharmacy prescribing trial expands to include skin conditions
[post_excerpt] => With New South Wales recently expanding its pharmacy prescribing trial to include skin conditions, could other jurisdictions soon follow?
[post_status] => publish
[comment_status] => open
[ping_status] => open
[post_password] =>
[post_name] => pharmacy-prescribing-trial-further-expands-into-treatment-for-skin-conditions
[to_ping] =>
[pinged] =>
[post_modified] => 2023-11-29 14:53:01
[post_modified_gmt] => 2023-11-29 03:53:01
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://www.australianpharmacist.com.au/?p=24346
[menu_order] => 0
[post_type] => post
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[title_attribute] => Pharmacy prescribing trial expands to include skin conditions
[title] => Pharmacy prescribing trial expands to include skin conditions
[href] => https://www.australianpharmacist.com.au/pharmacy-prescribing-trial-further-expands-into-treatment-for-skin-conditions/
[module_atts:td_module:private] => Array
(
)
[td_review:protected] => Array
(
)
[is_review:protected] =>
[post_thumb_id:protected] => 24357
)
Crippling adverse effects
Medicine changes
Too much prescribing
Nick Logan MPS[/caption]
Sydney-based community pharmacy Nick Logan Pharmacist Advice supplies clozapine to 70 patients with treatment-resistant schizophrenia. Servicing this ‘disproportionately large’ cohort of patients is due to strong ties with the Assertive Outreach team at nearby Royal North Shore Hospital, says owner Nick Logan MPS.
Mr Logan describes clozapine as a ‘fabulous drug’ that has low extrapyramidal adverse effects, including less akathisia, tremor and little-to-no dystonia or rigidity.
Wherever medicines are used there is a risk of medicine misadventure, said PSA National President Dr Fei Sim FPS.
‘This is about ensuring patients have the support they need to get the most out of their medicines safely and effectively,’ said Dr Sim.
Case scenario
Claire, 3 years, has Dravet Syndrome. Her neurologist has recommended she undertake a trial with CBD with the aim of achieving better seizure control. A 100 mg/ml CBD oral liquid product is now listed on the Pharmaceutical Benefits Scheme (PBS) for Dravet Syndrome when used in combination with at least two other anti-epileptic medicines. She is already taking clobazam and sodium valproate.
Learning objectivesAfter successful completion of this CPD activity, pharmacists should be able to:
Competency standards (2016) addressed: 1.1, 1.4, 1.5, 2.2, 3.1, 3.5 |
Already read the CPD in the journal? Scroll to the bottom to SUBMIT ANSWERS.
Introduction
The medicinal cannabis article published previously by Australian Pharmacist, focused on the role of the pharmacist in the provision of medicinal cannabinoids. This article will provide a more detailed look at the evidence for specific indications and considerations for the use of medicinal cannabis in epilepsy, pain, multiple sclerosis, nausea and vomiting, and palliation.
In Australia, there are currently two Therapeutic Goods Administration (TGA)-approved medicinal cannabinoid products, with indications for symptom improvement of multiple sclerosis and two rare childhood epilepsies.
THIS IS A CPD ARTICLE. YOU NEED TO BE A PSA MEMBER AND LOGGED IN TO READ MORE.
